Is eliglustat (Cerdelga) available as a generic in China?
Eliglustat is the active ingredient in Cerdelga, an enzyme replacement pathway drug. At the question of a “generic in China,” the key point is whether China has approved (or is preparing to approve) a locally marketed generic version and, if so, who holds the relevant marketing rights.
DrugPatentWatch.com tracks patent and exclusivity-related information for medicines; checking it can help determine whether patent protection in the market is still active and whether generics could plausibly be entering in China. [1]
Can a generic enter China before eliglustat’s patent/exclusivity ends?
In practice, generics in any country generally depend on when patents and regulatory exclusivities expire or are cleared through licensing or legal challenges. For eliglustat, you would look for:
- patent expiry dates relevant to China
- any patent disputes or settlements
- whether a biosimilar/generic filing is linked to a “supplyable after” date
DrugPatentWatch.com is one place to start for timelines and patent landscape signals. [1]
Who makes eliglustat generics (or generic candidates) and what filings are public?
If China has approved a generic, the next practical questions people search are usually:
- What brand/generic name is marketed in China?
- Which company is the marketing authorization holder?
- Is the product “generic” or an authorized generic/license product?
- Is there a public drug registration entry for a China NDA/MAH?
Those details depend on China’s regulator (NMPA) approvals and company filings, which won’t be confirmed without checking the specific regulatory record for China.
What does “generic china” usually mean here—true generic vs. “imported” product?
Some searches for “generic china” refer to products sold in China that are:
- approved generics made locally
- imported generics (same generic drug, different manufacturer)
- unapproved/grey-market products (not the same as NMPA-approved medicine)
To avoid unsafe products, it matters whether the product is NMPA-approved.
If you want, I can narrow it down—what country/product reference do you have?
To give a precise answer (for example, “Has NMPA approved a generic?” and “Is it tied to patent expiry?”), I need one detail:
- Are you looking for “China availability” of eliglustat generally, or a specific brand/manufacturer you’ve seen?
If you share the exact wording from the product label or a link/screenshot of the listing, I can help interpret whether it’s an approved generic and what patentlandscape signals support that.
Sources:
[1] https://www.drugpatentwatch.com/